Cross-linked polyester-based depot systems for sustained drug delivery: determining the relationship between composition, properties and performance

用于持续药物输送的基于交联聚酯的储库系统：确定成分、性质和性能之间的关系

• 批准号: 508274-2017
• 负责人: Allen, Christine
• 金额: $ 10万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=643786
• 关键词: Cross; linked; polyester; based; depot

There are currently more than 20 pharmaceutical products that include implantable, insertable or injectable**drug delivery systems that are formed from the copolymer poly(lactide-co-glycolide) (PLGA) and provide**sustained release of drug therapy over time. The sustained drug release that is achieved with a single**administration, eliminates the need for daily or weekly drug administrations and as a result has a profoundly**positive impact on a patient's quality of life, patient compliance and leads to significant reductions in health**care costs. These products are currently used to treat critical medical conditions including diabetes,**endometriosis, prostate cancer and schizophrenia. While PLGA-based systems have provided a delivery**solution to many drugs, it is clear, a new polymeric delivery system is needed to meet the needs of the**pharmaceutical industry. Given that each drug is unique in terms of its physico-chemical properties and that**polymer-drug interaction and compatibility are key metrics that influence the performance of polymeric**delivery formulations there is no single polymer that can serve as a universal material for formulation of all**drugs. For this reason, Pendant Biosciences (a Canadian company) has patented, and in collaboration with the**Allen laboratory filed an additional provisional patent application, on a flexible polymer platform that includes**recognized building blocks that produce cross-linked biocompatible systems for prolonged delivery of a wide**range of drugs. If successful, the proposed research will result in (1) identification of a lead drug-polymer**product for development by Pendant Biosciences; (2) a 'tool-box' of biocompatible polymer materials to**facilitate drug-delivery research in academic and industrial settings and (3) increased scientific awareness of**the physical and chemical metrics responsible for the performance of a drug-polymer combination product.

目前有超过20种药物产品，包括可植入的，可插入的或可注射的药物递送系统，这些药物递送系统由共聚物聚（丙交酯-乙交酯）（PLGA）形成，并随着时间的推移提供药物治疗的持续释放。通过单次给药实现的持续药物释放消除了每天或每周给药的需要，因此对患者的生活质量、患者依从性具有深刻的积极影响，并导致健康护理成本的显著降低。这些产品目前用于治疗包括糖尿病、子宫内膜异位症、前列腺癌和精神分裂症在内的严重疾病。虽然基于PLGA的系统为许多药物提供了递送解决方案，但很明显，需要一种新的聚合物递送系统来满足制药行业的需求。鉴于每种药物在其物理化学性质方面都是独特的，并且 ** 聚合物-药物相互作用和相容性是影响聚合物 ** 递送制剂性能的关键指标，因此没有单一聚合物可以用作所有 ** 药物制剂的通用材料。出于这个原因，Pendant Biosciences（一家加拿大公司）已经申请了专利，并与 ** 艾伦实验室合作提交了一项额外的临时专利申请，该专利涉及一种灵活的聚合物平台，其中包括 ** 公认的构建模块，可以产生交联的生物相容性系统，用于延长广泛的药物输送。如果成功，拟议的研究将导致（1）确定Pendant Biosciences开发的主要药物-聚合物 ** 产品;（2）生物相容性聚合物材料的“工具箱”，以 ** 促进学术和工业环境中的药物递送研究;（3）提高对负责药物-聚合物组合产品性能的物理和化学指标的科学认识。